The following full text is a publisher's version.

For additional information about this publication click this link. http://hdl.handle.net/2066/190776

Please be advised that this information was generated on 2018-05-04 and may be subject to change.
Effect of Vegan Fecal Microbiota Transplantation on Carnitine- and Choline-Derived Trimethylamine-N-Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome

Loek P. Smits, MD*; Ruud S. Kootte, MD*; Evgeni Levin, PhD; Andrei Prodan, PhD; Susana Fuentes, PhD; Erwin G. Zoetendal, PhD; Zeneng Wang, PhD; Bruce S. Levison, PhD; Maartje C. P. Cleophas, PhD; E. Marleen Kemper, PhD; Geesje M. Dallinga-Thie, PhD; Albert K. Groen, PhD; Leo A. B. Joosten, PhD; Mihai G. Netea, MD, PhD; Erik S. G. Stroes, MD, PhD; Willem M. de Vos, PhD; Stanley L. Hazen, MD, PhD; Max Nieuwdorp, MD, PhD

Background—Intestinal microbiota have been found to be linked to cardiovascular disease via conversion of the dietary compounds choline and carnitine to the atherogenic metabolite TMAO (trimethylamine-N-oxide). Specifically, a vegan diet was associated with decreased plasma TMAO levels and nearly absent TMAO production on carnitine challenge.

Methods and Results—We performed a double-blind randomized controlled pilot study in which 20 male metabolic syndrome patients were randomized to single lean vegan-donor or autologous fecal microbiota transplantation. At baseline and 2 weeks thereafter, we determined the ability to produce TMAO from d6-choline and d3-carnitine (eg, labeled and unlabeled TMAO in plasma and 24-hour urine after oral ingestion of 250 mg of both isotope-labeled precursor nutrients), and fecal samples were collected for analysis of microbiota composition. 18F-fluorodeoxyglucose positron emission tomography/computed tomography scans of the abdominal aorta, as well as ex vivo peripheral blood mononuclear cell cytokine production assays, were performed. At baseline, fecal microbiota composition differed significantly between vegans and metabolic syndrome patients. With vegan-donor fecal microbiota transplantation, intestinal microbiota composition in metabolic syndrome patients, as monitored by global fecal microbial community structure, changed toward a vegan profile in some of the patients; however, no functional effects from vegan-donor fecal microbiota transplantation were seen on TMAO production, abdominal aortic 18F-fluorodeoxyglucose uptake, or ex vivo cytokine production from peripheral blood mononuclear cells.

Conclusions—Single lean vegan-donor fecal microbiota transplantation in metabolic syndrome patients resulted in detectable changes in intestinal microbiota composition but failed to elicit changes in TMAO production capacity or parameters related to vascular inflammation.

Clinical Trial Registration—URL: http://www.trialregister.nl. Unique identifier: NTR 4338. (J Am Heart Assoc. 2018;7:e008342. DOI: 10.1161/JAHA.117.008342.)

Key Words: atherosclerosis • cardiovascular disease • cardiovascular imaging • inflammation • metabolism
Clinical Perspective

What Is New?

- Lean vegans have different microbiota composition and lower capacity to produce TMAO (trimethylamine-N-oxide) compared with obese omnivores.
- Single lean vegan-donor fecal microbiota transplantation in obese male patients with metabolic syndrome resulted in changes in intestinal microbiota composition, but this did not translate into altered carnitine- or choline-to-TMAO conversion, nor did it affect markers of arterial wall inflammation.
- This lack of effect might be explained by the residual capacity to convert carnitine to TMAO in vegans and by limited baseline differences in intestinal microbiota composition between vegans and omnivores in conjunction with a relatively short follow-up period of 2 weeks.

What Are the Clinical Implications?

- Our data oppose the previously stated hypothesis that the intestinal microbiota in vegans is incapable of carnitine-to-TMAO conversion.
- Nevertheless, this small pilot study was the first to directly assess the potential causal link among intestinal microbiota, TMAO metabolism, and arterial wall inflammation in humans.
- Larger and better powered intervention studies with longer follow-up periods are necessary to further unravel the link between vegan microbiota and atherosclerotic burden via TMAO metabolism.
- Establishing the presence of such a link would encourage new interventions to alleviate cardiovascular risk by directly targeting the intestinal microbiota.

Intestinal microbiota are increasingly recognized as a factor underlying the pathobiology of several disease states, including cardiovascular disease (CVD). The intestinal microbiota composition in patients with symptomatic CVD differs significantly from that in healthy controls.1,2 Moreover, DNA from intestinal microbiota has been recovered from human atherosclerotic plaques, suggesting a potentially contributory role of gut microbiota to atherosclerosis.1 Several potential mechanisms have linked altered intestinal microbiota composition and function to CVD. First, traditional cardiovascular risk factors, such as insulin resistance3 and, more recently, dyslipidemia,4 have been associated with altered intestinal microbiota composition. Because fecal microbiota transplantation (FMT) from lean to obese insulin-resistant individuals improved the metabolic profile in the latter group,5 these findings suggest a causal role for intestinal microbiota in CVD. Second, intestinal microbiota composition affects peripheral blood mononuclear cell (PBMC) production capacity,6 which was linked to increased vascular inflammation and atherosclerosis.7

The recent discovery of TMAO (trimethylamine-N-oxide), a novel intestinal microbiota–related metabolite involved in atherosclerosis, provides a more direct link between intestinal microbiota and CVD. Intestinal bacteria are capable of producing TMA (trimethylamine) from endogenous and dietary phosphatidylcholine, as well as from carnitine, a nutrient mainly present in animal-derived food products. TMA is subsequently oxidized in the liver to TMAO in a reaction catalyzed by host hepatic flavin monoxygenases, particularly flavin monooxygenase 3.8 Plasma TMAO levels were found to be related to incident CVD in large prospective observational studies, and animal-model studies suggest a potentially causal role for TMAO in atherogenesis.9–11 In support, TMAO increased atherosclerotic lesion size in mice.9 Interestingly, individuals on a vegan diet are known to have an altered intestinal microbiota composition,12,13 which might partly explain the diminished capacity to produce TMAO11 and the tendency toward decreased cardiovascular risk in vegans compared with omnivores.14 In contrast, omnivorous metabolic syndrome patients are known to have a 2-fold increased cardiovascular risk15 as well as increased TMAO production.16 Plasma TMAO level in metabolic syndrome patients has been found to be an independent risk factor for CVD-associated mortality,17 and TMAO production and associated atherosclerotic risk were transmittable by FMT in mice.18 In conjunction with the fact that inhibition of TMA lyase, a bacterial enzyme responsible for conversion of choline and carnitine to TMAO, reduced TMAO levels and thus atherosclerosis in mice,19 this underscores the need for assessing a potentially causal role of intestinal microbiota in human TMAO production and, eventually, cardiovascular risk.

In the present double-blind randomized controlled pilot study, we investigated whether single lean vegan-donor FMT in omnivorous metabolic syndrome patients affects the intestinal microbiota composition and, subsequently, the conversion of both choline and carnitine to TMAO and TMA, compared with autologous (own feces) FMT. Moreover, we assessed the effect of vegan-donor FMT on vascular inflammatory tone by measuring aortic wall vascular inflammation, as assessed using 18F-fluorodeoxyglucose (18F-FDG) uptake positron emission tomography/computed tomography (PET/CT) scanning, which is reported to be increased in metabolic syndrome patients.20 We also examined ex vivo cytokine production by PBMCs.21

Methods

The data, analytic methods, and study materials are available to other researchers for purposes of reproducing the results or replicating the procedure. The data are available from the corresponding author on reasonable request.
Study Design
In this double-blinded, randomized, controlled, pilot study, we compared the effect of FMT in 20 obese metabolic syndrome patients using either lean, vegan-donor feces (vegan-donor FMT, n=10) or feces from the patients themselves (autologous FMT, n=10). Participants were randomized using a 1:1 allocation ratio. At baseline and 2 weeks after FMT, an oral stable isotope–labeled choline and carnitine challenge test (CCCT) was performed, combined with 18F-FDG PET/CT scanning of the abdominal aorta. We also collected fasting blood samples for ex vivo cytokine production assays, as well as plasma, 24-hour urine, and fecal samples. Vegan donors (n=9) underwent all baseline experiments including the oral stable isotope–labeled carnitine challenge test.

All study procedures were performed at the Academic Medical Center (Amsterdam, the Netherlands). The research protocol was approved by the investigational review board of the Academic Medical Center and executed according to current Good Clinical Practice guidelines (Declaration of Helsinki) and applicable national law. Written informed consent was obtained from all participants before any study procedure was performed. The study was registered in the Dutch Trial Registry (registration number NTR 4338).

Study Population
Male obese participants of West European genetic background were recruited by newspaper advertisements and screened for characteristics of the metabolic syndrome. We included male adults (aged 21–69 years) who were obese (body mass index ≥30) but otherwise healthy and who fulfilled the criteria of the metabolic syndrome (fasting glucose ≥5.6 mmol/L and ≥2 of the following criteria: triglyceride levels ≥1.7 mmol/L; high-density lipoprotein cholesterol <1.0 mmol/L; blood pressure ≥130/85 mm Hg; waist circumference ≥102 cm), without a history of CVD, cholecystectomy, or immunodeficiency and without the use of any medication (including antibiotics and proton pump inhibitors within the preceding 3 months). Participants had to adhere to an omnivorous diet without using any type of food supplements, specifically choline- and/or carnitine-enriched products. Healthy, lean (body mass index 20–25), adult (aged 21–69 years) men of West European genetic backgrounds who adhered to a vegan diet were also recruited via newspaper advertisements to serve as feces donors. The detailed screening procedure for feces donors in our hospital has been published previously.22 In short, donors were initially screened using an extensive questionnaire addressing risk factors for potentially transmittable diseases. Subsequently, plasma and feces were screened for potential pathogenic parasites, bacteria, and viruses. In line with our recent publication,23 donors were screened for the presence of (antibodies to) human immunodeficiency virus; human T-lymphotropic virus; hepatitis A, B, and C; cytomegalovirus; Epstein–Barr virus; strongyloides; amebiasis, and lues. Presence of infection resulted in exclusion, although previous, nonactive infections with Epstein–Barr virus and cytomegalovirus were allowed. Donors were also excluded if screening of their feces revealed the presence of pathogenic parasites (eg, blastocystis hominis, dientamoeba fragilis, giardia lamblia), bacteria (Shigella, Campylobacter, Yersinia, Salmonella, enteropathogenic Escherichia coli, and Clostridium difficile) or viruses (noro-, rota-, astro-, adenovirus, noro (40/41/52), entero-, parecho-, and sapovirus). As an extra safety procedure, donors were again screened for contraindications directly before every feces donation by using a second questionnaire focusing on newly developed contraindications to donation. In addition, both metabolic syndrome patients and vegan donors had to adhere to their own diet during their participation in the study. To this end, participants recorded their diet in the 7 days preceding the CCCT via an online nutritional diary (http://mijn.voedingscentrum.nl/nl/).

Study Procedures
Choline and carnitine challenge test
After an overnight fast and plasma collection at time point 0 (t=0), participants orally ingested a capsule containing 250 mg of stable isotope–labeled d₆-choline10 together with a capsule containing 250 mg of stable isotope–labeled d₃- carnitine.11 Two hours thereafter, a standardized vegan meal, consisting of 2 slices of vegan bread with vegan jam, was given to all participants. Urine was collected in the 24 hours following stable isotope ingestion, and plasma was collected 2, 4, 6, and 24 hours after stable isotope ingestion. There were no dietary restrictions from 6 hours after start of the CCCT. In plasma (venous EDTA) and urine samples, 4 volumes of methanol containing 10 µmol/L d₆-TMA and d₇-TMAO were added to precipitate the protein. The supernatant was collected after centrifugation at 20 000g, 4°C, during 10 minutes and used for liquid chromatography/tandem mass spectrometry quantitation, as described previously.24 The distinct isotopologue (d₃/-d₆-) TMA and (d₃/-d₆-) TMAO and their respective internal standards were analyzed using high-performance liquid chromatography with online electrospray ionization tandem mass spectrometry utilizing positive MRM mode with characteristic parent-to-daughter ion transitions as follows: m/z 63→47, 66→47, 69→49, 79→62, 82→65, and 85→68 for d₃-TMA, d₅-TMA, d₇-TMA, d₅-TMAO, d₇-TMAO, and d₆-TMAO, respectively. This method has a high degree of precision with total coefficient of variance <7.0% for TMAO and TMA and their respective isotopologues.24
**Vegan FMT Does Not Change TMAO Production**

**Smits et al**

DOI: 10.1161/JAHA.117.008342

PBMC cytokine production capacity

PBMCs were isolated from venous EDTA blood, as obtained at the CCCT (t=0), using Ficoll-Paque density gradient centrifugation. The cells were subsequently cultured for 24 hours in the presence of 10 ng/mL *E. coli* lipopolysaccharide (*E. coli* serotype 055:B5), 1 × 10⁵ colony-forming units (CFU)/mL heat killed *E. coli*, 1 × 10⁶ CFU/mL *Bacteroides fragilis* (cultured in house), or 10 µg/mL oxidized low-density lipoprotein (isolated and oxidized, as described previously). IL-1β (interleukin 1β) and TNF-α (tumor necrosis factor α) concentrations in the supernatant were determined with commercially available ELISA kits from R&D Systems, and the ELISA kits for IL-6 and IL-10 were purchased from Sanquin, as published previously.

**Measurement of aortic wall inflammation by ¹⁸F-FDG PET/CT scan**

On the day following the CCCT, a PET/CT scan (Philips Gemini; Philips) of the abdominal aortic wall was performed 90 minutes after the infusion of ¹⁸F-FDG. The FDG uptake was assessed by drawing a region of interest of ≥5 subsequent slices of the abdominal aorta, starting at the most cranial part of the liver and moving caudally. The mean of the maximized standardized FDG uptake value (maximal pixel activity per region of interest) of the 5 slices was assessed by a blinded reader. To correct for blood pool activity, a target-to-background value was used by dividing the mean maximized standardized FDG uptake value by the mean background activity in 5 regions of interest in the lumen of the adjacent inferior vena cava.

**Fecal microbiota transplantation**

On the day of treatment, both the metabolic syndrome patients and the vegan donors provided the investigators with a fresh morning fecal sample, stored at 4°C. Patients thereafter received bowel lavage with 2 L of a macrogol solution (Klean-Prep; Norgine Pharmaceuticals) via a nasoduodenal tube. After bowel lavage and based on randomization, feces from either the donor (vegan-donor FMT) or the patient (autologous FMT) was used to prepare the infusate. The complete stool production was diluted with 500 mL of sterile saline (0.9%) and subsequently stirred and filtered, resulting in a 500-mL homogenized solution. Within 6 hours of collection of the fecal material, the solution was infused through the nasoduodenal tube. In contrast to other clinics, we prefer to use duodenal infusion for FMT administration rather than infusion via colonoscopy because of the potential role of the small intestine in metabolism, as well as logistical reasons and the low complication rate at our institution.

**Analysis of fecal microbiota composition**

DNA from fecal samples was isolated using repeated bead beating, described in detail elsewhere. Concentration and purity were assessed with a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific). The microbial composition was determined using a previously described and benchmarked custom-made phylogenetic microarray, the Human Intestinal Tract Chip (HITChip). This is a custom-made Agilent microarray containing ≈5500 specific oligonucleotide probes. In short, the full-length 16S rRNA gene was amplified, transcribed into RNA, labeled with the fluorescent dyes Cy3 and Cy5, and hybridized to the array. Each sample was hybridized twice with a Pearson correlation of >0.98 between replicates to ensure that reproducibility and raw signal intensities were normalized, as described previously.

The HITChip microarray can detect 1033 species-like bacterial phyotypes (level 3, >98% 16S rRNA gene sequence similarity) that represent the majority of the microbial diversity in the human intestine. These were summarized to 130 genuslike phylogenetic groups (level 2, >90% 16S rRNA gene sequence similarity), referred to as species and relatives. Diversity of the microbiota was quantified based on nonlogarithmized HITChip oligo-level signals by the Shannon index using the “vegan” package (R version 2013, Community ecology package). Probes were counted in each sample to measure richness by using an 80% quantile threshold for detection.

**Sample size calculation and end points**

In line with our previous proof-of-concept study on the effects of lean omnivorous donor FMT on insulin sensitivity in men with the metabolic syndrome and based on a murine study on FMT and TMAO, we aimed to detect a 20% reduction in postprandial incremental area under the curve (AUC) of plasma TMAO levels (from δ6-labeled choline and δ3-labeled carnitine) with vegan donor FMT with an SD of 15%, whereas a 5% difference was expected with autologous FMT. Using an unpaired 2-sided *t* test (with α=0.025 and 80% power), the estimated sample size needed was 18 metabolic syndrome patients for each treatment arm. Estimating dropout of 10%, we aimed to include 20 metabolic syndrome patients per arm. Moreover, we aimed to include 10 vegan FMT donors. Between October 2013 and November 2015, a total of 2×10 men with metabolic syndrome and 9 male vegan donors were included (1 donor was used for 2 vegan-donor FMTs). A futility analysis was performed based on postprandial TMAO changes and showed a conditional power of 11%, suggesting that even with 20 participants per treatment arm, we would not achieve significant differences after treatment. We therefore decided to prematurely terminate the study. The primary end point of the study was the change in incremental
AUC of postprandial TMAO from \( d_6 \)-labeled choline and \( d_3 \)-labeled carnitine as well as changes in intestinal microbiota composition 2 weeks after vegan-donor FMT. The secondary end points were effects of vegan-donor FMT on vessel wall inflammation, as assessed by \( ^{18} \text{F} \)-FDG PET/CT scan, as well as ex vivo PBMC-derived cytokine production.

**Randomization and blinding**

An independent physician used computerized block randomization, using blocks of 4 patients, to ensure balanced inclusion rates in case inclusion targets were not reached. This did not incorporate stratification to ensure equal demographic and metabolic parameters between both treatment groups. Treatment days were planned after ascertaining availability of a recipient and donor on the same day. Allocation of treatment was determined by chronologically following the randomization file. At the day of FMT, the independent physician revealed the intended treatment to the research assistant, who provided the trial physician with the fecal material from either the assigned donor or metabolic syndrome patient. The study participants (eg, vegan donors and metabolic syndrome patients) and all trial physicians (including all authors) were blinded for the treatment until completion of the trial.

**Statistical Analyses**

All data are presented as mean (SD) or median (interquartile range [IQR]), depending on the distribution of the data. Differences between vegan donors and metabolic syndrome patients were tested using a Student \( t \) test for normally distributed data and a Mann–Whitney \( U \) test for nonnormal distributed data. The effect of FMT on \( d_3 \) and \( d_6 \)-TMAO and -TMAO plasma and urine markers as well as \( ^{18} \text{F} \)-FDG uptake was tested using a paired \( t \) test or Wilcoxon signed rank test, depending on the data distribution. A \( P \) value <0.05 was considered significant. The microbiota data were corrected for multiple testing, as described below.

Fecal microbiota that allowed accurate discrimination among groups of patients (vegan-donor versus autologous FMT) were selected by means of the elastic net algorithm. The elastic net method is applicable to structured and high-dimensional data. It is a regularized method that combines the advantages of 2 techniques: LASSO and ridge regression as previously published by our group. This combination allows for the selection of the most important microbiota while taking the correlation (“grouping effect”) among them into account. We used an adapted version of the elastic net algorithm (with Hinge loss function). Although the microbiota identified by the elastic net algorithm frequently lead to statistically significant results, they can also be unstable. In our approach, we addressed this problem via a stability

**Results**

In total, we included 20 metabolic syndrome patients and 9 vegan feces donors. None of the included participants was prematurely lost to follow-up after randomization. However, technical failure prevented analyses of PET/CT scans for 3 metabolic syndrome patients (1 baseline scan before vegan-donor FMT, 1 baseline scan before autologous FMT, and 1 posttreatment scan after vegan-donor FMT) and 1 vegan donor. In addition, no incremental AUC for plasma \( d_3 \)-TMAO was available for 2 metabolic syndrome patients because of missing samples at time point 24 hours (\( t=24 \)) (1 before vegan-donor FMT, 1 before autologous FMT). Unlabeled
plasma TMAO and 24-hour urine TMA, TMAO, d₃-TMA, and d₃-TMAO excretion was available for all patients for baseline and after FMT.

Metabolic syndrome patients were older (55.0 versus 33.4 years, \( p = 0.002 \)), had higher body mass index (33.9 versus 22.9, \( P < 0.001 \)) and had increased cardiovascular risk profiles compared with vegan donors, as a result of the study design (Table). Cardiovascular risk factors were similar at baseline between metabolic syndrome patients randomized to treatment with autologous or vegan-donor FMT. No serious adverse events were reported in either study group. We also observed no changes in safety laboratory parameters (eg, hematology, renal function, liver chemistry) on vegan-donor FMT (Table S1), and vegan-donor FMT did not affect vital signs (eg, pulse rate, blood pressure; data not shown). In line, dietary intake was not affected by either vegan or autologous FMT (Tables S2 and S3). In the autologous FMT group, some baseline parameters significantly decreased with treatment (eg, hemoglobin, alanine aminotransferase, cholesterol, triglycerides) but remained within the normal range throughout follow-up.

### Baseline Fecal Microbiota Composition and TMAO Metabolism in Metabolic Syndrome and Vegan Participants

We observed a nonsignificant trend toward decreased fecal microbial diversity in vegans versus metabolic syndrome patients (Shannon index: 5.9 [IQR: 5.8–6.0] versus 6.0 [IQR: 5.9–6.1], \( p = 0.08 \); Figure 1A), although the variation within the metabolic syndrome group was rather large and the absolute difference small. Redundancy analysis showed a distinction in fecal microbiota composition between the vegan donors and the metabolic syndrome patients (Figure 1B). Among others, bacteria related to Anaerostipes caccae and Lachnobacterium were associated with a vegan diet, whereas several groups belonging to the Clostridium genus were related to metabolic syndrome patients (Figure 1C).

With respect to TMAO production, fasting plasma concentrations of TMAO (3.7 μmol/L [IQR: 2.7–4.9 μmol/L] versus 2.8 μmol/L [IQR: 1.9–3.4 μmol/L], \( P = 0.13 \); Figure 2A) did not differ significantly between metabolic syndrome patients and vegan donors. However, 24-hour urinary excretion of TMAO was significantly higher in metabolic syndrome patients versus vegan donors (529 μmol [IQR: 239–1407 μmol] versus 178 μmol [IQR: 98–338 μmol], \( P = 0.03 \)), whereas 24-hour urinary TMA excretion was not significantly different between both groups at baseline (10.3 μmol [IQR: 3.9–23.9 μmol] versus 7.6 μmol [IQR: 3.1–13.6 μmol], \( P = 0.35 \)).

To further study the capacity to convert choline and carnitine to TMA and TMAO, a d₃-carnitine/d-choline challenge test was performed. After oral administration of d₃-carnitine, a similar pattern was observed compared with unlabeled TMAO. Although not significant, postprandial plasma appearance of d₃-TMAO was higher in metabolic syndrome patients than vegans (AUC [in μmol/L per 24 hours]: 114 [IQR: 68–182] versus 53 [IQR: 0–155],

### Table. Baseline Characteristics

<table>
<thead>
<tr>
<th>Value</th>
<th>Metabolic Syndrome Patients, All (n=20)</th>
<th>Vegan Donors (n=9)</th>
<th>P Value</th>
<th>Metabolic Syndrome Patients, Autologous FMT (n=10)</th>
<th>Metabolic Syndrome Patients, Vegan-Donor FMT (n=10)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>55.0±8.2</td>
<td>33.4±14.8</td>
<td>0.002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>33.9±3.8</td>
<td>22.9±1.7</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse, bpm</td>
<td>65.9±12.5</td>
<td>70.7±9.9</td>
<td>0.32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>150.2±12.3</td>
<td>130.6±6.2</td>
<td>&lt;0.001</td>
<td>152.2±12.5</td>
<td>148.2±12.4</td>
<td>0.48</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>93.1±9.0</td>
<td>78.9±6.6</td>
<td>&lt;0.001</td>
<td>93.3±8.3</td>
<td>92.8±10.1</td>
<td>0.91</td>
</tr>
<tr>
<td>Glucose, mmol/L</td>
<td>6.0±0.8</td>
<td>5.1±0.3</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Insulin, mIU/L</td>
<td>126.1±55.3</td>
<td>50.9±31.2</td>
<td>0.001</td>
<td>107.7±45.5</td>
<td>144.5±60.3</td>
<td>0.14</td>
</tr>
<tr>
<td>HbA1C, mmol/mol</td>
<td>37.8±4.4</td>
<td>34.0±3.4</td>
<td>0.03</td>
<td></td>
<td></td>
<td>0.37</td>
</tr>
<tr>
<td>Cholesterol, mmol/L</td>
<td>5.3±0.8</td>
<td>4.1±1.2</td>
<td>0.02</td>
<td></td>
<td></td>
<td>0.90</td>
</tr>
<tr>
<td>HDL-C, mmol/L</td>
<td>1.1±0.2</td>
<td>1.3±0.3</td>
<td>0.28</td>
<td></td>
<td></td>
<td>0.74</td>
</tr>
<tr>
<td>LDL-C, mmol/L</td>
<td>3.3±1.0</td>
<td>2.5±1.0</td>
<td>0.1</td>
<td></td>
<td></td>
<td>0.37</td>
</tr>
<tr>
<td>Triglycerides, mmol/L</td>
<td>1.30 (1.05–1.53)</td>
<td>0.82 (0.53–0.90)</td>
<td>0.006</td>
<td>1.30 (1.06–1.57)</td>
<td>1.27 (1.01–1.56)</td>
<td>0.82</td>
</tr>
<tr>
<td>CRP, mg/mL</td>
<td>1.50 (0.88–4.38)</td>
<td>0.50 (0.40–0.80)</td>
<td>0.005</td>
<td>1.90 (1.15–4.50)</td>
<td>1.45 (0.80–4.25)</td>
<td>0.65</td>
</tr>
</tbody>
</table>

Data are depicted as mean±SD or median (interquartile range), depending on their distribution. \( p < 0.05 \) was considered significant. BMI indicates body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; FMT, fecal microbiota transplantation; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
$P = 0.12$), and urinary excretion of both d$_3$-TMA (AUC [in $\mu$mol/L per 24 hours]: 3.7 [IQR: 1.2–11.1] versus 0.9 [IQR: 0–1.4], $P = 0.006$) and d$_3$-TMAO (AUC [in $\mu$mol/L per 24 hours]: 562 [IQR: 225–793] versus 54 [IQR: 0–224], $P = 0.002$) was significantly increased in metabolic syndrome patients versus vegan donors (Figure 2B). In line, plasma appearance of d$_3$-carnitine was significantly higher in vegans compared with metabolic syndrome patients. Remarkably, d$_6$-labeled choline —and, consequently, d$_6$-TMA and d$_6$-TMAO in plasma and in urine—was almost absent after oral d$_6$-choline administration (Figure S1) in both metabolic syndrome patients and vegans, with no baseline difference between groups.
Fecal Microbiota Composition and TMAO Metabolism With FMT

We found no changes in fecal microbiota diversity (Shannon index) 2 weeks after either vegan donor FMT (from 6.0 [IQR: 5.9–6.1] to 6.1 [IQR: 5.9–6.2], P=0.260) or autologous FMT (from 6.0 [IQR: 5.9–6.0] to 6.0 [IQR: 5.7–6.1], P=0.721; Figure 3A). However, vegan-donor FMT did affect intestinal microbiota composition in metabolic syndrome patients, with changes toward a more veganlike profile in some, but not all, patients (Figure 3B). Compared with autologous FMT, changes in fecal microbiota abundance with vegan FMT were seen in, among others, several groups belonging to the Lachnospiraceae, including bacteria related to Bryantella...
formatexigens and Megamonas hypermegale as well as L bovis. In contrast, autologous FMT resulted in minor shifts in microbiota composition and was primarily associated with changes in the abundance of bacteria related to Alcaligenes faecalis and Akkermansia (Figure 3C). With respect to TMAO, vegan-donor FMT did not affect fasting plasma TMAO levels or

Figure 3. The effect of lean vegan-donor FMT in fecal microbiota diversity and composition. A, Changes in fecal microbiota diversity 2 weeks after lean vegan-donor or autologous FMT in obese metabolic syndrome patients, expressed as Shannon index. Data are depicted as box-and-whisker plots. *P<0.05 was considered significant. B, RDA plot showing the changes in fecal microbiota composition in obese metabolic syndrome patients 2 weeks after either lean vegan-donor or autologous FMT. C, Spider plot depicting individual fecal microbiota genera that showed different changes in abundance in metabolic syndrome patients after either lean vegan-donor or autologous FMT. The axis of the spider plot reflects the amount of change (L2 norm) of the bacterial species on autologous (green) or lean vegan-donor (red) FMT. Auto FMT indicates autologous fecal microbiota transplantation; Donor FMT, lean vegan donor fecal microbiota transplantation; FMT, fecal microbiota transplantation; Placebo, autologous fecal microbiota transplantation; RDA, redundancy analysis; t=0/2w, time point 0/2 weeks.
24-hour urinary excretion of labeled and unlabeled TMA or TMAO (Figure 2 and 2B, Figure S1). Although autologous FMT did not influence plasma TMAO levels, and despite the large variation, it did result in a significant increase in urinary excretion of d3-TMAO (from 562 [IQR: 200–625] to 683 [IQR: 434–933] μmol/24 hours, \( P=0.03 \)).

**18F-FDG PET/CT Scan on FMT**

To study the effect of vegan-donor FMT on vascular inflammation, **18F-FDG PET/CT** scans of the abdominal aortic wall were performed at baseline and 2 weeks after FMT. FDG uptake in the aortic wall at baseline was not significantly different between metabolic syndrome patients and vegan donors (maximized target-to-background: 3.25 ± 0.8 versus 2.83 ± 0.9, \( P=0.27 \); Figure 4). Neither vegan-donor FMT nor autologous FMT altered aortic wall FDG uptake (Figure 4). Baseline and posttreatment maximized target-to-background values were, respectively, 3.49 ± 1.1 and 3.43 ± 0.9 (\( P=0.90 \)) in the vegan donor FMT group and 3.15 ± 0.5 and 3.59 ± 1.1 (\( P=0.28 \)) for the autologous FMT group.

**Figure 4.** **18F-FDG PET/CT** results of lean vegan donors vs obese metabolic syndrome patients and posttreatment changes. Shown are PET/CT results comparing obese metabolic syndrome patients with lean vegan FMT donors at baseline and treatment-induced change after either autologous or lean vegan-donor FMT. Data are depicted as means with SDs. \( P<0.05 \) was considered significant. Auto FMT indicates autologous fecal microbiota transplantation; Donor FMT, lean vegan donor fecal microbiota transplantation; FDG, fluorodeoxyglucose; MetS, obese omnivorous metabolic syndrome subjects; PET/CT, positron emission tomography/computed tomography; t=0/2w, time point 0/2 weeks; TBR Max, maximum target-to-background ratio; Vegans, lean vegan fecal microbiota transplantation donors.

**FMT Effects on Cytokine Production Capacity**

Before and 2 weeks after FMT, PBMCs were isolated from whole blood and ex vivo stimulated with different stimuli to measure cytokine production (IL-1β, IL-6, IL-10, TNF-α). Oxidized low-density lipoprotein production differed between vegans and metabolic syndrome patients on 3 of 4 stimuli, but other cytokines were similar at baseline (Figure S2). Moreover, autologous FMT resulted in increased IL-10 and IL-1β production after *Bacteroides* stimulation, whereas we did not observe any treatment-induced changes within the vegan-donor FMT group.

**Discussion**

In the present double-blind, randomized, controlled, pilot study, we show that lean vegan donor FMT in obese metabolic syndrome patients results in altered fecal microbiota composition. Unexpectedly, these alterations do not translate into significant effects on choline- or carnitine-to-TMA or -TMAO conversion. In line, no effect of vegan donor FMT was seen on surrogate markers of cardiovascular risk including vascular inflammation (aortic **18F-FDG** uptake assessed by PET/CT) and cytokine production capacity by PBMCs. These data showed that in the time window of 2 weeks, the therapeutic effect of a single vegan-donor FMT was not sufficient to alter systemic TMAO levels in obese patients with increased cardiovascular risk due to metabolic syndrome.

Underscoring previous observations, our data confirmed that only limited baseline differences exist in fecal microbiota diversity between omnivores and vegans.\(^{12,13}\) In vegans, we found increased relative abundance of fecal *Lachnospiraceae*, including butyrate-producing bacteria related to *L bovis* and *Anaerostipes*,\(^{9,13,35,36}\) whereas metabolic syndrome patients were enriched in *Clostridiales*, which have been associated with TMA production.\(^{11}\) In support of a previous publication, metabolic syndrome patients are characterized by an increased capacity to convert carnitine to TMA and, subsequently, TMAO.\(^{11}\) Although it remains to be proven in larger cohorts, a recent meta-analysis by Heianza et al\(^{37}\) suggests that higher conversion of carnitine to TMA and TMAO may result in a 1.4-fold higher risk of CVD. Meanwhile, the similarity in unlabeled TMA excretion suggests a difference in hepatic flavin monoxygenase activity between metabolic syndrome patients and vegan donors. Indeed, altered hepatic flavin monoxygenase has been linked to insulin resistance in animal models.\(^{38}\) In contrast to the near absence of d3-TMAO production in the study by Koeth et al,\(^{11}\) the vegans in our study were capable of some capacity to convert d3-carnitine to TMAO, as demonstrated by the appearance of d3-TMAO in plasma and urine after d3-carnitine challenge. This difference might reflect the stricter definition...
of a vegan diet used in the studies by Koeth et al, which required >1 preceding year of using no animal products in the diet. The near absence of both d₆-choline and d₆-TMA and -TMAO in plasma and urine is remarkable compared with the d₃-TMAO concentrations within this study and previous reports on labeled choline metabolism in humans. ¹⁰ It should be noted that in the study by Tang et al,¹⁰ heavy isotope–labeled phosphatidylcholine and not choline was used. The in vitro stability of the d₆-choline compound was tested and shown to be very stable (data not shown); it thus appears likely that the free d₆-choline, despite being provided at a greater molar level than isotope–labeled phosphatidylcholine previously, was almost not absorbed by the (small) intestine, limiting TMA and subsequent (hepatic) TMAO production. Unfortunately, we did not obtain post-CCCT fecal samples to determine fecal excretion of d₆-labeled choline to support this hypothesis.

Two weeks after vegan donor FMT, fecal samples of metabolic syndrome patients were significantly enriched in short-chain fatty acid producers B formatexigenis and relatives³⁹ and M hypermegale and relatives,¹⁰ the latter of which is known as a non–TMA-producing genus.⁴¹ In contrast, autologous FMT affected the relative abundance of bacterial genera related to A faecalis and Akkermansia, with the latter related to beneficial metabolic health.⁴² Although the mechanism is unclear, it might be that the aerobic treatment of autologous feces has selected the oxygen-tolerant Akkermansia⁴³ and A faecalis.⁴⁴ These bacterial strains may subsequently occupy the niche in the fecal microbiota that was created by eradication of other anaerobic species. Despite these changes in intestinal microbiota composition, and in contrast to animal work,¹⁸,⁴⁵ and human antibiotic intervention studies,¹⁰ vegan-donor FMT was not able to reduce (both native and d₃-labeled) TMAO production in metabolic syndrome patients, whereas autologous FMT was associated with increased excretion of d₃-TMAO. With regard to the latter, the concomitant increase in A faecalis, which is known to generate TMA,⁴⁶ may provide some explanation for this intriguing finding. Vegan-donor FMT led to a shift toward vegan-like microbiota composition in some, but not all, recipients. This could be related to the limited baseline fecal microbiota differences and continuation of an omnivorous diet after vegan-donor FMT, which together may have resulted in a limited effect size of the FMT on TMAO conversion. We did not choose to put metabolic syndrome patients on a vegan diet after vegan-donor FMT because we have previously reported metabolic changes after a single donor FMT without a dietary intervention, and the introduction of a standardized diet is known to affect intestinal microbiota composition; this would include bias.⁴⁷ The heterogeneity in vegan-donor fecal microbiota composition, as a consequence of using multiple vegan FMT donors, might also have added to the variation in microbiota changes seen following vegan-donor FMT. However, we recently showed that the donor FMT effect on metabolism is largely driven by the receiving patient rather than the donor.⁵² Albeit modest and lower compared with metabolic syndrome patients, our vegan donors still had a residual capacity to convert carnitine to TMAO, which may explain that d₆-TMA and d₆-TMAO derived from d₆-choline remained almost absent in plasma and urine after vegan-donor FMT. Moreover, we did not observe differences in FDG uptake at baseline between vegans and metabolic syndrome patients. This was surprising because previous trials have reported on increased FDG uptake in metabolic syndrome patients versus controls,⁴⁸ and a vegan diet has been associated with decreased inflammation and protection from metabolic syndrome.⁴⁹ Vegan-donor FMT did not affect aortic wall ¹⁸F-FDG uptake or ex vivo cytokine production, both surrogate parameters for an atherogenic proinflammatory state. The nonsignificant changes in TMAO production on vegan FMT align with the observations of Seldin et al showing a linear relation between amount of TMAO on aortic vascular endothelial cell inflammation in an animal model of CVD.⁵⁰ In combination with this limited TMAO-lowering potential of vegan-donor FMT, the timing of the posttreatment measurements (2 weeks after FMT) might have been too fast after intervention to observe a maximal effect on TMAO production and PET/CT imaging. Nevertheless, FMT is capable of (permanently) changing the gut microbiota from 2 weeks after intervention,²² and we previously showed significant reductions in PET/CT signal of the aortic wall in a similarly short-term time window (between 3 days and 8 weeks) after intervention.⁵¹,⁵²

Our study has certain limitations. First, we assessed short-term outcome of vegan-donor FMT in male obese west European participants, possibly precluding generalization of our findings to other patient groups and not studying long-term outcome. Second, as a consequence of our randomized controlled trial design and in combination with the intensive study program for the participants, the sample size of our study is small. We tried to minimize the risk for important type II errors imposed by this small sample size by the use of sensitive (stable isotope–based) outcome parameters that, in previous studies, rendered significant effect¹⁰,¹¹; however, the large variation in TMAO metabolism limits strong conclusions regarding part of our hypotheses. Third, participants adhered to their own omnivorous diet after intervention, which, in hindsight, could have attenuated treatment-induced changes. Finally, dietary records are notoriously inaccurate.⁵³ Nevertheless, the main strength of the present study is that we investigated the relationship among intestinal microbiota, TMAO production, and surrogate markers of vascular inflammation using feces from participants with a longstanding vegan diet.

In conclusion, in this pilot study, single vegan-donor FMT altered intestinal microbiota composition but was not able to affect TMAO production or an atherogenic proinflammatory state in patients with metabolic syndrome. The small
(underpowered) sample size and short-term follow-up period might have contributed to the lack of noticed effect. Because lean-donor FMT can alter both fecal microbiota composition and glucose metabolism in similarly size groups of metabolic syndrome patients, our data underscore the need for time-interval–dependent metabolic flux studies in humans to study reproducibility and validation of this mode of intervention in cardiometabolic disease. Furthermore, the selection of donors and recipients based on high versus low TMAO levels and baseline fecal microbiota composition, and not simply metabolic syndrome status, would have potentially larger capability of monitoring for change in TMAO production potential in recipients of FMT in future studies. Consequently, further studies disentangling the role of intestinal microbiota composition in TMAO production and CVD are recommended. 19

Sources of Funding
This project was supported by a CVON grant (CVON-IN CONTROL) by the Dutch Heart Foundation and in part by a grant from a Transatlantic Networks of Excellence Award from the Leducq Foundation. Cleophas is supported by a grant of the Dutch Arthritis Foundation (nr. 12-2-303). Joosten is supported by a Competitiveness Operational Programme grant of the Romanian Ministry of European Funds (P_37_762). Netea was supported by an ERC Consolidator Grant (310372) and de Vos in part by an Advanced ERC Grant (250172) from the European Research Council. Netea and de Vos received a Spinoza Award of the Netherlands Organization for Scientific Research (NWO). de Vos was further supported by a SIAM Gravitation Grant of NWO (024.002.002). Wang and Hazen were supported in part by grants from the National Heart, Lung, and Blood Institute of the National Institutes of Health and the Office of Dietary Supplements (R01DK106000, R01HL135920, HL126827, R01HL103866, R01HL130819). Nieuwdorp is supported by a ZONMW-VIDI grant 2013 (016.146.327) and a Dutch Heart Foundation CVON Young Talent Grant 2013 (on which Prodan is appointed). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.

Disclosures
Nieuwdorp and de Vos are founders and in the Scientific Advisory Board of Caelus Pharmaceuticals. Levin is founder of Horaiwon B.V. de Vos is in the Scientific Advisory Board of Chr. Hansen, Hoersholm, Denmark, and the Nestle Institute for Health Science, Lausanne, Switzerland. Wang and Hazen are named as co-inventors on pending patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. Wang and Hazen report that they have the right to receive royalty payment for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab and Proctor & Gamble. Hazen reports having been paid as a consultant for the following companies: Proctor & Gamble. Hazen reports receiving research funds from Pfizer Inc, Proctor & Gamble and Takeda. None of these possible conflicts of interest bear direct relation to the outcomes of this specific study with regard to patents or royalties. The remaining authors have no disclosures to report.

References
SUPPLEMENTAL MATERIAL
Table S1. Safety parameters in obese metabolic syndrome subjects before and after FMT.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Autologous FMT t=0</th>
<th>Autologous FMT t=2w</th>
<th>P-value</th>
<th>Vegan donor FMT t=0</th>
<th>Vegan donor FMT t=2w</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (mmol/l)</td>
<td>9.6 ± 0.4</td>
<td>9.2 ± 0.5</td>
<td>0.01</td>
<td>9.5 ± 0.6</td>
<td>9.6 ± 0.6</td>
<td>0.54</td>
</tr>
<tr>
<td>Thrombocytes (*10^9/l)</td>
<td>229.1 ± 20.8</td>
<td>239.1 ± 39.2</td>
<td>0.23</td>
<td>239.9 ± 48.3</td>
<td>243.2 ± 56.9</td>
<td>0.71</td>
</tr>
<tr>
<td>Leucocytes (*10^9/l)</td>
<td>6.3 ± 1.2</td>
<td>6.0 ± 0.8</td>
<td>0.28</td>
<td>5.6 ± 1.2</td>
<td>5.6 ± 0.9</td>
<td>0.87</td>
</tr>
<tr>
<td>CRP (mg/ml)</td>
<td>1.9 [1.2 – 4.5]</td>
<td>3.6 [1.2 – 5.1]</td>
<td>0.59</td>
<td>1.5 [0.8 – 4.3]</td>
<td>2.2 [1.0 – 5.8]</td>
<td>0.51</td>
</tr>
<tr>
<td>Creatinine (umol/l)</td>
<td>80.4 ± 13.1</td>
<td>81.4 ± 14.0</td>
<td>0.57</td>
<td>85.7 ± 10.7</td>
<td>85.0 ± 9.0</td>
<td>0.61</td>
</tr>
<tr>
<td>Bilirubin (iU/l)</td>
<td>10.0 ± 4.5</td>
<td>10.1 ± 3.3</td>
<td>0.87</td>
<td>9.3 ± 2.1</td>
<td>9.5 ± 3.0</td>
<td>0.74</td>
</tr>
<tr>
<td>ALT (iU/l)</td>
<td>37.2 ± 12.9</td>
<td>29.4 ± 8.4</td>
<td>0.01</td>
<td>35.1 ± 8.4</td>
<td>34.9 ± 13.3</td>
<td>0.93</td>
</tr>
<tr>
<td>AST (iU/l)</td>
<td>30.2 ± 11.6</td>
<td>24.1 ± 5.2</td>
<td>0.14</td>
<td>26.7 ± 5.4</td>
<td>26.4 ± 12.9</td>
<td>0.92</td>
</tr>
<tr>
<td>AP (iU/l)</td>
<td>74.8 ± 18.2</td>
<td>71.0 ± 16.5</td>
<td>0.13</td>
<td>71.1 ± 17.1</td>
<td>58.9 ± 26.7</td>
<td>0.19</td>
</tr>
<tr>
<td>γGT (iU/l)</td>
<td>44.2 ± 26.5</td>
<td>33.7 ± 13.7</td>
<td>0.08</td>
<td>49.8 ± 26.0</td>
<td>46.9 ± 34.9</td>
<td>0.62</td>
</tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>6.18 ± 0.9</td>
<td>6.0 ± 0.6</td>
<td>0.61</td>
<td>5.8 ± 0.5</td>
<td>5.9 ± 0.6</td>
<td>0.62</td>
</tr>
<tr>
<td>Insulin (miU/l)</td>
<td>107.7 ± 45.5</td>
<td>121.0 ± 76.5</td>
<td>0.38</td>
<td>146.0 ± 63.7</td>
<td>140.7 ± 64.8</td>
<td>0.78</td>
</tr>
<tr>
<td>HbA1C (mmol/mol)</td>
<td>38.7 ± 3.6</td>
<td>38.3 ± 3.9</td>
<td>0.22</td>
<td>36.9 ± 5.1</td>
<td>37.4 ± 3.5</td>
<td>0.48</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.3 ± 0.8</td>
<td>5.0 ± 0.7</td>
<td>0.04</td>
<td>5.3 ± 0.9</td>
<td>5.3 ± 0.9</td>
<td>0.94</td>
</tr>
<tr>
<td>LDL-c (mmol/l)</td>
<td>3.1 ± 1.3</td>
<td>3.2 ± 0.5</td>
<td>0.68</td>
<td>3.5 ± 0.7</td>
<td>3.5 ± 0.8</td>
<td>0.85</td>
</tr>
<tr>
<td>HDL-c (mmol/l)</td>
<td>1.2 ± 0.2</td>
<td>1.2 ± 0.2</td>
<td>0.78</td>
<td>1.1 ± 0.2</td>
<td>1.2 ± 0.2</td>
<td>0.47</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.3 [1.1 – 1.6]</td>
<td>1.0 [0.7 – 1.5]</td>
<td>0.005</td>
<td>1.3 [1.0 – 1.6]</td>
<td>1.3 [1.0 – 2.2]</td>
<td>0.92</td>
</tr>
</tbody>
</table>

Data are depicted as means ± SDs or medians ± IQRs, based on their distribution. A p-value < 0.05 was considered significant. ALT = alanine transaminase; AP = alkaline phosphatase; AST = aspartate transaminase; CRP = c-reactive protein; FMT = fecal microbiota transplantation; γGT = gamma-glutamyltransferase; HbA1c = glycated hemoglobin; HDL-c = high-density lipoprotein cholesterol; IQR = interquartile range; LDL-c = low-density lipoprotein cholesterol; SD = standard deviation.
Table S2. Daily nutritional intake in lean vegan donors and obese metabolic syndrome subjects.

<table>
<thead>
<tr>
<th></th>
<th>Metabolic syndrome patients (n=19)</th>
<th>Vegan donors (n=8)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calories (kcal/day)</td>
<td>2038.7 ± 381.9</td>
<td>2068.3 ± 264.6</td>
<td>0.86</td>
</tr>
<tr>
<td>Fat (g/day)</td>
<td>76.1 ± 16.3</td>
<td>72.8 ± 17.7</td>
<td>0.75</td>
</tr>
<tr>
<td>Carbohydrates (g/day)</td>
<td>203.9 ± 70.0</td>
<td>245.0 ± 46.5</td>
<td>0.20</td>
</tr>
<tr>
<td>Protein (g/day)</td>
<td>84.7 ± 16.5</td>
<td>69.2 ± 5.5</td>
<td>0.09</td>
</tr>
<tr>
<td>Fiber (g/day)</td>
<td>18.0 ± 4.2</td>
<td>43.4 ± 19.2</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Shown is daily dietary intake, divided in 5 food constituents, as calculated from a 7-day dietary record.

Data are depicted as means + SDs. A p-value < 0.05 was considered significant.
Table S3. Daily nutritional intake of obese metabolic syndrome subjects before and after FMT.

<table>
<thead>
<tr>
<th></th>
<th>Autologous FMT t=0</th>
<th>Autologous FMT t=2w</th>
<th>P-value</th>
<th>Vegan donor FMT t=0</th>
<th>Vegan donor FMT t=2w</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calories (kcal/day)</td>
<td>1951.6 ± 379.8</td>
<td>1728.7 ± 289.8</td>
<td>0.13</td>
<td>2010.4 ± 343.2</td>
<td>2128.6 ± 499.1</td>
<td>0.33</td>
</tr>
<tr>
<td>Fat (g/day)</td>
<td>72.7 ± 13.7</td>
<td>59.2 ± 7.6</td>
<td>0.13</td>
<td>75.5 ± 17.1</td>
<td>74.3 ± 18.2</td>
<td>0.86</td>
</tr>
<tr>
<td>Carbohydrates (g/day)</td>
<td>178.3 ± 56.1</td>
<td>184.9 ± 65.3</td>
<td>0.53</td>
<td>209.7 ± 71.4</td>
<td>218.8 ± 94.6</td>
<td>0.51</td>
</tr>
<tr>
<td>Protein (g/day)</td>
<td>89.2 ± 19.4</td>
<td>76.8 ± 12.7</td>
<td>0.11</td>
<td>78.2 ± 9.4</td>
<td>82.1 ± 13.1</td>
<td>0.32</td>
</tr>
<tr>
<td>Fiber (g/day)</td>
<td>17.4 ±5.9</td>
<td>18.1 ± 4.6</td>
<td>0.51</td>
<td>17.8 ± 3.2</td>
<td>17.1 ± 4.3</td>
<td>0.56</td>
</tr>
</tbody>
</table>

Shown is daily dietary intake, divided in 5 food constituents, as calculated from a 7-day dietary record.

Data represent dietary recording of metabolic syndrome subjects, in the autologous and vegan FMT group, both before and after treatment. Data are depicted as means ± SDs. A p-value < 0.05 was considered significant. FMT = fecal microbiota transplantation.
Figure S1. D6-choline plasma and urine metabolites.

Graphs showing the 24-hour appearance of d6-choline in plasma (A), the 24-hour appearance of d6-TMAO (from d6-choline) in plasma (B) and the total urinary excretion of d6-TMAO and d6-TMA in the 24 hours following oral ingestion of 250mg d6-labeled choline (C-D). Data are depicted as box-and-whisker plots. No significant differences were found. Auto FMT = autologous fecal microbiota transplantation; Donor FMT = lean vegan donor fecal microbiota transplantation; iAUC = incremental area under the curve; MetS = obese omnivorous metabolic syndrome patients; TMA = trimethylamine; TMAO = trimethylamine-N-oxide; Vegans = lean vegan FMT donors.
Figure S2A-D. Monocyte cytokine production after lean vegan donor or autologous FMT.

Depicted is the ex vivo monocyte production of 4 different cytokines (A: IL1-β; B: IL6; C: IL10; D: TNF-α), after in total 6 stimuli of which RPMI served as the control stimulus. Data are depicted as box-and-whisker plots. A p-value < 0.05 was considered significant and is marked with an asterisk. Auto = autologous fecal microbiota transplantation; Allo = lean vegan donor fecal microbiota transplantation; e. coli = Escherichia coli; IL = interleukin; LPS = lipopolysaccharide; oxLDL = oxidized low-density lipoprotein; RPMI = Roswell Park Memorial Institute medium; TNFα = tumor-necrosis factor α.
C.

IL10

IL10 (pg/ml)

0
200
400
600
800
1000

*
Effect of Vegan Fecal Microbiota Transplantation on Carnitine– and Choline–Derived Trimethylamine–N–Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome


J Am Heart Assoc. 2018;7:e008342; originally published March 26, 2018;
doi: 10.1161/JAHA.117.008342

The Journal of the American Heart Association is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/7/7/e008342